Radioligand therapy from Novartis yields positive phase III study results for prostate cancer
Novartis’ Phase III VISION study showed positive findings in overall survival and radiographic progression-free survival for patients who received 177Lu-PSMA-617, a targeted radioligand therapy for progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
04.05.2021